# Study of XmAb412 in Healthy Participants

> **NCT07713485** · PHASE1 · RECRUITING · sponsor: **Xencor, Inc.** · enrollment: 128 (estimated)

## Conditions studied

- Not Applicable - Healthy Adult Participants

## Interventions

- **DRUG:** XmAb412 Monoclonal Bispecific Antibody
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07713485
- **Lead sponsor:** Xencor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-13
- **Primary completion:** 2027-05
- **Final completion:** 2028-03
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07713485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07713485, "Study of XmAb412 in Healthy Participants". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07713485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*